Discontinued — last reported Q3 '22
Intercontinental Exchange Acquisitions decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $30.00M to $0.00. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -26.8% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.00M | $4.00M | $56.00M | $14.75M | $14.75M | $14.75M | $14.75M | $2.55B | $2.55B | $2.55B | $2.55B | $0.00 | $8.00M | $0.00 | $30.00M | $11.00M | $2.00M | $6.00M | $0.00 |
| QoQ Change | — | -33.3% | >999% | -73.7% | +0.0% | +0.0% | +0.0% | >999% | +0.0% | +0.0% | +0.0% | -100.0% | — | -100.0% | — | -63.3% | -81.8% | +200.0% | -100.0% |
| YoY Change | — | — | — | — | +145.8% | +268.8% | -73.7% | >999% | >999% | >999% | >999% | -100.0% | -99.7% | -100.0% | -98.8% | — | -75.0% | — | -100.0% |